Other OTC - Delayed Quote USD

Amyris, Inc. (AMRSQ)

0.0020 -0.0030 (-60.00%)
As of May 6 at 10:00 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Hermanus Kieftenbeld Interim CEO, CFO & Chief Administration Officer 644.71k -- 1966
Mr. Peter DeNardo Senior Director of Investor Relations & Corporate Communications -- -- --
Ms. Doris Choi General Counsel & Secretary -- -- 1978
Ms. Christine Ofori Chief People Officer -- -- --
Ms. Beth Baker Bannerman Chief Engagement & Sustainability Officer -- -- --
Ms. Daya Fields President of Pipette & Purecane -- -- --
Ms. Annie Tsong Chief Product & Technology Strategy Officer -- -- --
Mr. Philip J. Gund Chief Restructuring Officer -- -- --
Mr. Oreste Fieschi President of Sweeteners & Ingredients -- -- 1958
Ms. Catherine Gore President of Biossance -- -- --

Amyris, Inc.

5885 Hollis Street
Suite 100
EmeryVille, CA 94608
United States
510 450 0761 https://amyris.com
Full Time Employees: 
1,598

Description

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

Amyris, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • May 07, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 23, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 08, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 28, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 12, 2024
    POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
    See Full Filing

Upcoming Events

May 09, 2024 - May 21, 2024
Amyris, Inc. Earnings Call

Related Tickers